{"id":58825,"date":"2021-06-14T17:42:31","date_gmt":"2021-06-14T15:42:31","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=58825"},"modified":"2021-06-14T18:05:50","modified_gmt":"2021-06-14T16:05:50","slug":"vaccino-novavax-arriva-entro-fine-settembre-sarebbe-molto-efficace","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/vaccino-novavax-arriva-entro-fine-settembre-sarebbe-molto-efficace\/","title":{"rendered":"Novavax vaccine arrives by the end of September: it would be very effective"},"content":{"rendered":"
\n

In support of countries for now neglected by the distribution of vaccines, Novavax's NVX-CoV2373 should arrive in September and will require authorizations all over the world.<\/span><\/p>\n<\/div>\n

Sputnik news \u2013 June 14, 2021<\/a><\/p>\n

\n
\"\"Very early a new vaccine against the coronavirus<\/a> will be added to the list of those approved internationally, and it is the American Novavax which for the moment has made it known that the experimental results have also given positive results on the variants with the 90% coverage<\/strong>.<\/div>\n
<\/div>\n<\/div>\n

In September it could apply for approval for emergency use from the US drug regulator, the FDA, the European EMA and other countries.<\/span><\/strong><\/p>\n

The study was conducted on 29,960 people and the vaccine demonstrated an efficacy of 90.4%.<\/p>\n

\n

Novavax will initially be able to make it available to the international community 100 million doses of vaccine.<\/strong><\/p>\n<\/div>\n

\n

Novavax's third way: protein-based vaccine<\/span><\/strong><\/p>\n

\"\"<\/a>Novavax brings a novelty in terms of pharmaceutical techniques and technologies used in the fight against the coronavirus. The pharmaceutical company has in fact opted for a protein-based vaccine, which contains tiny particles obtained from a laboratory-produced version of the Spike protein present on the surface of the pandemic coronavirus.<\/p>\n<\/div>\n

The vaccine also uses an adjuvant (Matrix-M1), which is a substance that helps strengthen the immune responses stimulated by the vaccine.<\/p>\n

\n
No blood clotting or heart disease problems were detected in the subjects who received the double injection.<\/div>\n
<\/div>\n<\/div>\n

Where will the NVX-CoV2373 vaccine go<\/span><\/p>\n

\n
to use the Novavax NVX-CoV2373 vaccine<\/a>, easy to transport and store, will be mainly low- and middle-income countries, said the pharmaceutical company's president of research and development Gregory M. Glenn.<\/div>\n<\/div>\n
\n
\n
\n

The French vaccine<\/span><\/strong><\/p>\n<\/div>\n<\/div>\n

The European Commission is also in talks with the French company Valneva with which, however, no contract has yet been signed for any 30 million doses.<\/p>\n

Valneva's vaccine, Vla2001, is based on a fourth technology that uses inactivated coronavirus Sars-CoV-2 particles.<\/div>\n
\n
Related news<\/div>\n
\n\n\n\n\n\n\n\n
Title<\/a><\/th>\nTopics<\/a><\/th>\nYear<\/a><\/th>\nLinks<\/th>\nDocument<\/th>\nNotes<\/th>\n<\/tr>\n<\/thead>\n
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the US and Mexico<\/td>\nCOVID-19<\/td>\n2020<\/td>\nDownloads<\/a><\/td>\nUpdated May 10, 2021<\/td>\n<\/tr>\n
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the UK<\/td>\nCOVID-19<\/td>\n2020<\/td>\nDownloads<\/a><\/td>\nUpdated April 5, 2021<\/td>\n<\/tr>\n
Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa<\/td>\nCOVID-19<\/td>\n2020<\/td>\nDownloads<\/a><\/td>\nUpdated January 25, 2021<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial<\/a><\/p>\n

Note:<\/p>\n

NVX-CoV 7 is a vaccine designed to provide protection against COVID-19. Designed from the genetic sequence of COVID-19, recombinant nanoparticle technology was used to generate antigens derived from the spike protein of the coronavirus. In combination with the proprietary adjuvant Matrix-M\u2122, NVX-CoV 7 has been shown in preclinical studies to bind efficiently with human receptors targeted by the virus, critical for effective vaccine protection.<\/em><\/p>\n

Novavax's proprietary saponin-based Matrix-M\u2122 adjuvant demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells to the injection site and improving antigen presentation in local lymph nodes, increasing the immune response. In particular Matrix-M is composed of 40 nanometric particles based on saponin extracted from the bark of Quillaja saponaria Molina together with cholesterol and phospholipids.<\/em><\/p>\n

Novavax is a US company operating in the field of biotechnology. Founded in 1987, it is headquartered in Gaithersburg, Maryland: it was included in the Russell 2000 Index and is listed on the Nasdaq.<\/em><\/p>\n

The company is primarily engaged in vaccine development and has facilities in Rockville, Maryland, and Uppsala, Sweden. His research has never produced any vaccine that has come on the market. Starting in 2020, the study and development of a vaccine against SARS-CoV-2, the virus responsible for the COVID-19 pandemic, began. This vaccine, called NVX-CoV2373, reached Phase III of development in January 2021.<\/em><\/p>\n

 <\/p>\n

<\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

In supporto ai Paesi per ora trascurati dalla distribuzione dei vaccini, a settembre dovrebbe giungere il NVX-CoV2373 di Novavax che richieder\u00e0 autorizzazioni in tutto il mondo. Sputnik news – 14 giugno 2021 Molto presto un nuovo vaccino contro il coronavirus si aggiunger\u00e0 alla lista di quelli approvati internazionalmente, ed \u00e8 lo statunitense Novavax che per …<\/p>","protected":false},"author":4,"featured_media":58836,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[39],"class_list":["post-58825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-vaccini"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/58825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=58825"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/58825\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/58836"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=58825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=58825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=58825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}